Articles tagged with: OPD5

Press Releases»

[ by | Oct 19, 2020 2:51 am | Comments Off ]
Oncopeptides Has Submitted An Investigational New Drug Application To FDA For The Second Drug Candidate From The PDC Platform

Stockholm, Sweden (Press Release) – Oncopeptides AB (publ) (Nasdaq Stock­holm: ONCO) to­day an­nounces that the Com­pany has sub­mitted an Inves­ti­ga­tional New Drug (IND) appli­ca­tion to the U.S. Food and Drug Admin­istra­tion (FDA), for OPD5 – a sec­ond drug can­di­date based on the pro­pri­e­tary Peptide Drug Con­ju­gate plat­form (PDC).

Oncopeptides plans to ini­ti­ate clin­i­cal de­vel­op­ment of OPD5 with an open-label phase 1, dose escalation study on safety and tol­er­a­bil­ity of OPD5 as a myeloablative regi­men fol­lowed by au­tol­o­gous stem cell trans­plan­ta­tion in patients with re­lapsed re­frac­tory mul­ti­ple myeloma. The spe­cif­ic for­mu­la­tion enables admin­istra­tion of high …

Read the full story »